Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New analgesic agents revealed in patent literature

May 13, 2005

Recent patents impart therapeutic agents for neurological disorders

May 13, 2005

20-HETE synthesis inhibitor TS-011 beneficial in hemorrhagic and ischemic stroke

May 13, 2005

Phase II/III trial of CEP-1347 in Parkinson's disease discontinued

May 13, 2005

Preliminary phase I results with PDE4 inhibitor IPL-455903

May 13, 2005

GW and Bayer amend Sativex marketing agreement

May 13, 2005

Recent patents cover new agents for depression, anxiety, psychosis, etc.

May 11, 2005

Approval letter for Biovail's Tramadol ODT

May 11, 2005

Phase III efficacy results for Oravescent in breakthrough cancer pain

May 11, 2005

Corcept starts new phase III trial with mifepristone in PMD

May 10, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...